tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Ascendis Pharma price target raised to $230 from $210 at RBC Capital

RBC Capital analyst Luca Issi raised the firm’s price target on Ascendis Pharma (ASND) to $230 from $210 and keeps an Outperform rating on the shares. The company posted another strong beat for Yorvipath despite some FX headwinds while prescriber base also expanded from 1,000 to 1,750 docs, the analyst tells investors in a research note.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1